Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 20.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,178 shares of the company’s stock after acquiring an additional 2,102 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Deciphera Pharmaceuticals were worth $196,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Deerfield Management Company L.P. Series C lifted its position in Deciphera Pharmaceuticals by 2.8% in the third quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock valued at $87,738,000 after acquiring an additional 190,580 shares during the last quarter. Deutsche Bank AG raised its holdings in Deciphera Pharmaceuticals by 36.7% during the third quarter. Deutsche Bank AG now owns 254,671 shares of the company’s stock worth $3,239,000 after purchasing an additional 68,435 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth about $1,167,000. Dark Forest Capital Management LP increased its stake in shares of Deciphera Pharmaceuticals by 18.9% during the 3rd quarter. Dark Forest Capital Management LP now owns 60,216 shares of the company’s stock worth $766,000 after purchasing an additional 9,553 shares in the last quarter. Finally, Diversified Trust Co purchased a new position in Deciphera Pharmaceuticals during the fourth quarter worth $193,000. Institutional investors and hedge funds own 70.96% of the company’s stock.

Deciphera Pharmaceuticals Price Performance

Shares of NASDAQ:DCPH opened at $25.38 on Wednesday. The business has a 50-day moving average of $16.91 and a two-hundred day moving average of $15.07. The firm has a market capitalization of $2.09 billion, a PE ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $25.47.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The firm had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. During the same quarter last year, the firm posted ($0.60) earnings per share. Deciphera Pharmaceuticals’s revenue for the quarter was up 32.9% compared to the same quarter last year. As a group, research analysts anticipate that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on DCPH shares. Jonestrading restated a “hold” rating and issued a $25.60 target price on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. JPMorgan Chase & Co. lifted their target price on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. Stifel Nicolaus increased their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, April 29th. Finally, Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Deciphera Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $24.17.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.